Annual report pursuant to Section 13 and 15(d)

Segment reporting

v2.4.0.6
Segment reporting
12 Months Ended
Jul. 31, 2012
Segment Reporting Disclosure [Text Block]

Note 15 – Segment reporting


The Company has three reportable segments: Life Sciences, Clinical Labs and Therapeutics. The Company’s Life Sciences segment develops, manufactures, and markets products to research and pharmaceutical customers. The Clinical Labs segment provides diagnostic services to the health care community. The Company’s Therapeutics segment conducts research and development activities for therapeutic drug candidates. The Company evaluates segment performance based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as “Other” consist of corporate general and administrative costs which are not allocable to the three reportable segments.


Management of the Company assesses assets on a consolidated basis only and therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies.


The following financial information represents the operating results of the reportable segments of the Company:


Year ended July 31, 2012


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Clinical
Labs

 

Life
Sciences

 

Therapeutics

 

Other

 

Consolidated

 

 

 


 


 


 


 


 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Clinical laboratory services

 

$

59,403

 

 

 

 

 

 

 

$

59,403

 

Product revenues

 

 

 

$

37,722

 

 

 

 

 

 

37,722

 

Royalty and license fee income

 

 

 

 

5,958

 

 

 

 

 

 

5,958

 

 

 



 



 



 



 



 

Total revenues

 

 

59,403

 

 

43,680

 

 

 

 

 

 

103,083

 

 

 



 



 



 



 



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of clinical laboratory services

 

 

36,305

 

 

 

 

 

 

 

 

36,305

 

Cost of product revenues

 

 

 

 

19,668

 

 

 

 

 

 

19,668

 

Research and development

 

 

299

 

 

4,308

 

$

1,686

 

 

 

 

6,293

 

Selling, general and administrative

 

 

20,856

 

 

18,305

 

 

 

$

8,767

 

 

47,928

 

Provision for uncollectible accounts receivable

 

 

4,987

 

 

117

 

 

 

 

 

 

5,104

 

Legal

 

 

262

 

 

536

 

 

 

 

2,926

 

 

3,724

 

Impairment charges

 

 

 

 

24,540

 

 

 

 

 

 

24,540

 

 

 



 



 



 



 



 

Total operating expenses

 

 

62,709

 

 

67,474

 

 

1,686

 

 

11,693

 

 

143,562

 

 

 



 



 



 



 



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating loss

 

 

(3,306

)

 

(23,794

)

 

(1,686

)

 

(11,693

)

 

(40,479

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income (expense)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest

 

 

(5

)

 

23

 

 

 

 

3

 

 

21

 

Other

 

 

28

 

 

27

 

 

 

 

22

 

 

77

 

Foreign exchange loss

 

 

 

 

(540

)

 

 

 

 

 

(540

)

 

 



 



 



 



 



 

 

Loss before income taxes

 

$

(3,283

)

$

(24,284

)

$

(1,686

)

$

(11,668

)

$

(40,921

)

 

 



 



 



 



 



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization included above

 

$

1,092

 

$

3,217

 

$

43

 

$

125

 

$

4,477

 

 

 



 



 



 



 



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Share-based compensation included in above:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of clinical laboratory services

 

$

10

 

 

 

 

 

 

 

 

$

10

 

Research and development

 

 

 

$

4

 

 

 

 

 

 

4

 

Selling, general and administrative

 

 

49

 

 

59

 

 

 

$

597

 

 

705

 

 

 



 



 



 



 



 

Total

 

$

59

 

$

63

 

 

 

$

597

 

$

719

 

 

 



 



 



 



 



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Capital expenditures

 

$

921

 

$

443

 

 

 

$

 

$

1,364

 

 

 



 



 



 



 



 


Year ended July 31, 2011


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Clinical
Labs

 

Life
Sciences

 

Therapeutics

 

Other

 

Consolidated

 

 

 


 


 


 


 


 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Clinical laboratory services

 

$

52,762

 

 

 

 

 

 

 

 

$

52,762

 

Product revenues

 

 

 

$

41,830

 

 

 

 

 

 

41,830

 

Royalty and license fee income

 

 

 

 

7,437

 

 

 

 

 

 

7,437

 

 

 



 



 



 



 



 

Total revenues

 

 

52,762

 

 

49,267

 

 

 

 

 

 

102,029

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of clinical laboratory services

 

 

31,682

 

 

 

 

 

 

 

 

31,682

 

Cost of product revenues

 

 

 

 

22,137

 

 

 

 

 

 

22,137

 

Research and development

 

 

 

 

5,784

 

$

2,022

 

 

 

 

7,806

 

Selling, general and administrative

 

 

18,426

 

 

17,855

 

 

 

$

8,910

 

 

45,191

 

Provision for uncollectible accounts receivable

 

 

4,415

 

 

16

 

 

 

 

 

 

4,431

 

Legal

 

 

387

 

 

726

 

 

 

 

2,597

 

 

3,710

 

 

 



 



 



 



 



 

Total operating expenses

 

 

54,910

 

 

46,518

 

 

2,022

 

 

11,507

 

 

114,957

 

 

 



 



 



 



 



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating (loss) income

 

 

(2,148

)

 

2,749

 

 

(2,022

)

 

(11,507

)

 

(12,928

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income (expense)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest

 

 

(5)

 

 

2

 

 

 

 

14

 

 

11

 

Other

 

 

30

 

 

(3

)

 

 

 

18

 

 

45

 

Foreign exchange gain

 

 

 

 

49

 

 

 

 

 

 

49

 

 

 



 



 



 



 



 

(Loss) income before income taxes

 

$

(2,123

)

$

2,797

 

$

(2,022

)

$

(11,475

)

$

(12,823

)

 

 



 



 



 



 



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization included above

 

$

1,012

 

$

3,282

 

$

47

 

$

128

 

$

4,469

 

 

 



 



 



 



 



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Share-based compensation included in above:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of clinical laboratory services

 

$

10

 

 

 

$

 

 

 

$

10

 

Research and development

 

 

 

$

14

 

 

 

 

 

 

14

 

Selling, general and administrative and legal

 

 

61

 

 

84

 

 

 

$

880

 

 

1,025

 

 

 



 



 



 



 



 

Total

 

 

71

 

 

98

 

$

 

$

880

 

$

1,049

 

 

 



 



 



 



 



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Capital expenditures

 

$

834

 

$

389

 

$

 

$

 

$

1,223

 

 

 



 



 



 



 



 


Year ended July 31, 2010


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Clinical
Labs

 

Life Sciences

 

Therapeutics

 

Other

 

Consolidated

 

 

 


 


 


 


 


 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Clinical laboratory services

 

$

44,178

 

 

 

 

 

 

 

 

44,178

 

Product revenues

 

 

 

$

43,111

 

 

 

 

 

$

43,111

 

Royalty and license fee income

 

 

 

 

9,793

 

 

 

 

 

 

9,793

 

 

 



 



 



 



 



 

Total revenues

 

 

44,178

 

 

52,904

 

 

 

 

 

 

97,082

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of clinical laboratory services

 

 

29,570

 

 

 

 

 

 

 

 

 

29,570

 

Cost of product revenues

 

 

 

 

22,547

 

 

 

 

 

 

22,547

 

Research and development

 

 

 

 

7,202

 

$

2,502

 

 

 

 

9,704

 

Selling, general and administrative

 

 

18,503

 

 

19,800

 

 

 

$

10,092

 

 

48,395

 

Provision for uncollectible accounts receivable

 

 

3,432

 

 

48

 

 

 

 

 

 

3,480

 

Legal

 

 

222

 

 

145

 

 

 

 

1,379

 

 

1,746

 

Litigation settlement

 

 

 

 

 

 

 

 

3,698

 

 

3,698

 

 

 



 



 



 



 



 

Total operating expenses

 

 

51,727

 

 

49,742

 

 

2,502

 

 

15,169

 

 

119,140

 

 

 



 



 



 



 



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating (loss) income

 

 

(7,549

)

 

3,162

 

 

(2,502

)

 

(15,169

)

 

(22,058

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income (expense)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest

 

 

 

 

(5

)

 

 

 

24

 

 

19

 

Other

 

 

46

 

 

(8

)

 

 

 

6

 

 

44

 

Foreign exchange loss

 

 

 

 

(266

)

 

 

 

 

 

(266

)

 

 



 



 



 



 



 

(Loss) income before income taxes

 

$

(7,503

)

$

2,883

 

$

(2,502

)

$

(15,139

)

$

(22,261

)

 

 



 



 



 



 



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization included above

 

$

982

 

$

3,110

 

$

52

 

$

125

 

$

4,269

 

 

 



 



 



 



 



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Share-based compensation included in above:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of clinical laboratory services

 

$

12

 

 

 

 

$

 

 

 

$

12

 

Research and development

 

 

 

$

14

 

 

 

 

 

 

14

 

Selling, general and administrative and legal

 

 

78

 

 

114

 

 

 

$

952

 

 

1,144

 

 

 



 



 



 



 



 

Total

 

$

90

 

$

128

 

$

 

$

952

 

$

1,170

 

 

 



 



 



 



 



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Capital expenditures

 

$

1,728

 

$

1,450

 

$

11

 

$

62

 

$

3,251

 

 

 



 



 



 



 



 


Geographic financial information is as follows:


 

 

 

 

 

 

 

 

 

 

 

Net sales to unaffiliated customers:

 

2012

 

2011

 

2010

 

 

 


 


 


 

United States

 

$

87,776

 

$

85,691

 

$

82,873

 

Switzerland

 

 

6,802

 

 

8,508

 

 

7,037

 

United Kingdom

 

 

2,728

 

 

2,825

 

 

2,507

 

Other international countries

 

 

5,777

 

 

5,005

 

 

4,665

 

 

 



 



 



 

Total

 

$

103,083

 

$

102,029

 

$

97,082

 

 

 



 



 



 

 

 

 

 

 

 

 

 

 

 

 


 

 

 

 

 

 

 

 

 

 

 

Long-lived assets at July 31,

 

2012

 

2011

 

2010

 

 

 


 


 


 

United States

 

$

25,081

 

$

44,028

 

$

45,439

 

Switzerland

 

 

2,223

 

 

8,958

 

 

7,063

 

United Kingdom

 

 

618

 

 

2,857

 

 

2,944

 

Other international countries

 

 

426

 

 

1,850

 

 

1,723

 

 

 



 



 



 

Total

 

$

28,348

 

$

57,693

 

$

57,169

 

 

 



 



 



 


The Company’s reportable segments are determined based on the services they perform, the products they sell, and the royalties and license fee income they earn, not on the geographic area in which they operate. The Company’s Clinical Labs segment operates 100% in the United States with all revenue derived there. The Life Sciences segment earns product revenue both in the United States and foreign countries and royalty and license fee income in the United States. The following is a summary of the Life Sciences segment revenues attributable to customers located in the United States and foreign countries:


 

 

 

 

 

 

 

 

 

 

 

 

 

2012

 

2011

 

2010

 

 

 


 


 


 

United States

 

$

28,372

 

$

32,928

 

$

38,695

 

Foreign countries

 

 

15,308

 

 

16,339

 

 

14,209

 

 

 



 



 



 

 

 

$

43,680

 

$

49,267

 

$

52,904